The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Vaccine
; 41(41): 6064-6071, 2023 09 22.
Article
in En
| MEDLINE
| ID: mdl-37640568
ABSTRACT
The ongoing evolution and emergence of SARS-CoV-2 variants have raised concerns regarding the efficacy of existing vaccines and therapeutic agents. This study aimed to investigate the immunogenicity of an aluminum hydroxide (Alum) and CpG adjuvanted inactivated vaccine (IAV) candidate against SARS-CoV-2 in mice. A comparison was made between the immune response of mice vaccinated with the Alum+CpG adjuvant IAV and those vaccinated with the Alum adjuvant IAV. Mice immunized with Alum+CpG adjuvant IAV demonstrated high antibody titers and a durable humoral immune response, as well as a Th1-type cellular immune response. Notably, compared to Alum alone vaccine, the Alum+CpG adjuvant IAV induced significantly higher proportions of GC B cells in the splenocytes of immunized mice. Importantly, the changes in inflammatory cytokine levels in the sera of mice vaccinated with the Alum+CpG adjuvant IAV followed a similar trend to that of the Alum adjuvant IAV, which had been proven safe in clinical trials. Overall, our results demonstrate that Alum+CpG adjuvant has the potential to serve as a novel adjuvant, thereby providing valuable insights into the development of vaccine formulations.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Aluminum Hydroxide
/
COVID-19
Limits:
Animals
Language:
En
Journal:
Vaccine
Year:
2023
Type:
Article
Affiliation country:
China